The World Dermatological Market Analysis & Forecasts 2007-2022

Table of Contents

Chapter 1 Executive Summary

• 1.1 Dermatological Market Overview
• 1.2 Aims, Scope and Format of the Report
• 1.3 Structure of the Report

Chapter 2 Introduction of Overall Skin Diseases and Dermatological Treatments

• 2.1 The Structure of the Skin
  • 2.1.1 Hair
  • 2.1.2 Swear and Sebaceous Glands
  • 2.1.3 Nails
• 2.2 The physiological Role of Skin
  • 2.2.1 Protection
  • 2.2.2 Sensory Perception
  • 2.2.3 Storage
  • 2.2.4 Absorption/Vitamin D Formulation
  • 2.2.5 Temperature Regulation
• 2.3 Differences in Skin Due to Gender
• 2.4 The effects of Age on Skin Structure
• 2.5 Inflammation and Histamine Release
• 2.6 Common Skin Problems
  • 2.6.1 Blackheads
  • 2.6.2 Boils
  • 2.6.3 Cold Sores
  • 2.6.4 Freckles
  • 2.6.5 Moles
  • 2.6.6 Pimples
  • 2.6.7 Warts
• 2.7 Common Skin Treatments
  • 2.7.1 Topical Preparations
    • 2.7.1.1 Creams and Semisolid Emulsions
    • 2.7.1.2 Ointments
    • 2.7.1.3 Lotions
    • 2.7.1.4 Solutions
    • 2.7.1.5 Occlusive Therapy
  • 2.7.2 Cleansing Agents
  • 2.7.3 Protectant Powders and Hydrophilic Polymers
  • 2.7.4 Anti-Infective Agents
  • 2.7.5 Anti-Inflammatory Agents

Chapter 3 Treatments and Dermatological Market Analysis for Acne

• 3.1 The Introduction of Acne
  • 3.1.1 Pathogenesis and Causations
    • 3.1.1.1Pathogenesis
    • 3.1.1.2 Causations
  • 3.1.2 The Diagnosis of Acne
• 3.2 Symptoms Definitions
  • 3.2.1 Comedone
  • 3.2.2 Papule
  • 3.2.3 Pustule
  • 3.2.4 Macule
  • 3.2.5 Nodule
  • 3.2.6 Cyst
• 3.3 Patient analysis
  • 3.3.1 Women and Acne
  • 3.3.2 Social Impact of Acne
• 3.4 Treatments
  • 3.4.1 Topical Pharmaceutical Treatments
    • 3.4.1.1 Topical Antibiotics
    • 3.4.1.2 Azlaic Acid
    • 3.4.1.3 Benzoyl Peroxide
    • 3.4.1.4 Sulfonamide (Sulfacet-R)
    • 3.4.1.5 Topical Retinoids
  • 3.4.2 Oral Pharmaceutical Treatments
    • 3.4.2.1 Oral Retinoids
    • 3.4.2.2 Oral Antibiotics
    • 3.4.2.3 The Estrogen (cyproterone/ethinylestradiol)
    • 3.4.2.4 Corticosteroids
    • 3.4.2.5 Other Hormonal Therapies
  • 3.4.3 Other Treatments for Acne
• 3.5 Acne World Market Outlook
  • 3.5.1 Current Events
  • 3.5.2 Global Market Analysis
  • 3.5.3 Topical Acne Treatments Market Analysis
  • 3.5.4 Top Oral Acne Treatments Analysis
  • 3.5.5 Sales Forecasts
    • 3.5.5.1 Topical Acne Treatments
    • 3.5.5.2 Oral Acne Treatments
    • 3.5.5.3 Conclusion

Chapter 4 Treatments and Dermatological Market Analysis for Psoriasis

• 4.1 The Introduction of Psoriasis
  • 4.1.1 Causations
  • 4.1.2 Symptoms
  • 4.1.3 Type
  • 4.1.4 Complications
• 4.2 Patient analysis
  • 4.2.1 Prevalence
• 4.3 Treatments
  • 4.3.1 Topical Agents
    • 4.3.1.1 Anthralin
    • 4.3.1.2 Coal tar
    • 4.3.1.3 Retinoids
    • 4.3.1.4 Vitamin D3 (Calcipotripol)
    • 4.3.1.5 Topical corticosteroids (steroids)
    • 4.3.1.6 Emollients4.3.1.7 Keratolytics 4.3.1.8 Patients' Preference for Topical Agents
  • 4.3.2 Systemic Treatments
    • 4.3.2.1 Oral Retinoid Systemic Agents
    • 4.3.2.2 Biologic Agents
    • 4.3.2.3 Phototherapy and Photochemotherapy
• 4.4 Psoriasis/ Pruritus World Market Outlook
  • 4.4.1 Current Global Psoriasis Market
  • 4.4.2 Leading Brands Analysis
    • 4.4.2.1 Dovonex/Daivonex/Daivobet/Taclonex (calciportiene/betamethasone)
    • 4.4.2.2 Raptiva
    • 4.4.2.3 Zorac (tazarotene)
    • 4.4.2.4 Soriatane and Neotigason
  • 4.4.3 Sales Forecasts

Chapter 5 Treatments and Dermatological Market Analysis for Skin Infection

• 5.1 The Introduction of Skin Infection
  • 5.1.1 Bacterial Skin Infections
  • 5.1.2 Bacteria-infected Patients Analysis
• 5.2 Fungal Skin Infections
  • 5.2.1 Dermatophyte Infections
  • 5.2.2 Fungal-infected Patient Analysis
  • 5.2.3 Treatments for fungal infections
    • 5.2.3.1 Ringworm Treatments
    • 5.2.3.2 Tinea Corporis Treatments
    • 5.2.3.3 Tinea Pedis Treatments
    • 5.2.3.4 Tinea Unguium Treatments
    • 5.2.3.5 Tinea Capitis Treatments
• 5.3 Viral Infections
  • 5.3.1 Herpes Simplex
  • 5.3.2 Chicken Pox (Varicella)
  • 5.3.3 Herpes Zpster
  • 5.3.4 Warts (Verrucae)
  • 5.3.5 Viral-infected Patients Analysis
  • 5.3.6 Treatments
• 5.4 Skin Parasites
  • 5.4.1 Scabies
  • 5.4.2 Lice
• 5.5 World Market Outlook for Dermatological-Infective Treatments
  • 5.5.1 Current Market Analysis
  • 5.5.2 Key Brands Analysis
    • 5.5.2.1 Anti-Vrial Treatments
    • 5.5.2.2 Anti-Fungal Treatments
    • 5.5.2.3 Anti-Bacterial Treatments
  • 5.5.3 Sales Forecasts

Chapter 6 Dermatitis, Rosacea, Urticaria and Alopecia

• 6.1 Introduction of Dermatitis
  • 6.1.1 Atopic dermatitis
  • 6.1.2 Contact dermatitis
  • 6.1.3 Seborrheic dermatitis
  • 6.1.4 Dermatitis Patient analysis
• 6.2 The Introduction of Rosacea
  • 6.2.1 Symptoms
  • 6.2.2 Types and Causations
  • 6.2.3 Patient analysis
• 6.3 The Introduction of Urticaria
  • 6.3.1 Acute Urticaria
  • 6.3.2 Chronic Urticaria
  • 6.3.3 Physical Urticaria
  • 6.3.4 Dermatographic Urticaria
  • 6.3.5 Patient Analysis
• 6.4 Introduction of Alopecia
  • 6.4.1 Alopecia Areata
  • 6.4.2 Androgenic Alopecia
  • 6.4.3 Telogen effluvium
  • 6.4.4 Trichotillomania and traction alopecia
  • 6.4.5 Prevalence of Alopecia
• 6.5 Treatments for Dermatitis, Rosacea and Urticaria
  • 6.5.1 Treatments of Dermatitis
  • 6.5.2 Treatments for Rosacea
    • 6.5.2.1 Topical Treatments
    • 6.5.2.2 Systemic Treatments for Rosacea
    • 6.5.2.3 Conclusion
  • 6.5.3 Treatments for Urticaria
  • 6.5.4 Treatments for Alopecia
    • 6.5.4.1 Alopecia Areata
    • 6.5.4.2 Androgenic Alopecia
    • 6.5.4.3 Telogen Effluvium
• 6.6 Global Market Analysis for Dermatitis, Rosacea, Urticaria and Alopecia Treatment Market
  • 6.6.1 Corticosteroids
    • 6.6.1.1 Leading Brands Analysis
    • 6.6.1.2 Sales Forecasts
  • 6.6.2 Other Dermatologic Treatments Market
    • 6.6.2.1 Leading Brand Analysis
    • 6.6.2.2 Sales Forecasts

Chapter 7 Treatments and Dermatological Market Analysis for Aesthetic Dermatology

• 7.1 The Introduction of Aesthetic Dermatology
• 7.2 Surgical and Non-surgical Market
• 7.3 Expenditure
• 7.4 Treatments
  • 7.4.1 Superficial Chemical Peeling
  • 7.4.2 Dermabrasion
  • 7.4.3 Laser Skin Resurfacing
  • 7.4.4 Electrosurgical Resurfacing
  • 7.4.5 Superfluous Hair Removal
  • 7.4.6 Liposuction
  • 7.4.7 Surgery
  • 7.4.8 Soft-Tissue Augmentation/Dermal Fillers
    • 7.4.8.1 Collagen Injections
    • 7.4.8.2 Body Fat Transfer and Body Sculpturing
    • 7.4.8.3 Hyaluronic Acid Injections
  • 7.4.9 Topical Treatments
  • 7.4.10 Botulinum Toxin
• 7.5 Aesthetic Dermatology World Market Outlook
  • 7.5.1 Leading Product Analysis
  • 7.5.2 Sales Forecasts

Chapter 8 Key Player and Pipeline Analysis

• 8.1 Allergan
  • 8.1.1 Marketed Dermatological Product Portfolio
    • 8.1.1.1 Neuromodulator Product
    • 8.1.1.2 Skin Care Product Line
    • 8.1.1.3 Facial Aesthetics
    • 8.1.1.4 Other Aesthetics Products
  • 8.1.2 R&D Pipeline Analysis
  • 8.1.3 Strategic Analysis
  • 8.1.4 Conclusion
• 8.2 GlaxoSmithKilne
  • 8.2.1 Marketed Dermatological Product Portfolio
  • 8.2.2 R&D
  • 8.2.3 Strategic Analysis and Conclusion
• 8.3 Johnson&Johnson
  • 8.3.1 Marketed Dermatological Product Portfolio
  • 8.3.2 R&D Pipeline Analysis
  • 8.3.3 Strategic Analysis
• 8.4 L' Oreal
  • 8.4.1 Marketed Dermatological Product Portfolio
  • 8.4.2 Leading Brands Analysis
  • 8.4.3 Strategic Analysis
• 8.5 Leo Pharma
  • 8.5.1 Marketed Dermatological Product Portfolio
  • 8.5.2 R&D Pipeline Analysis
  • 8.5.3 Strategic Analysis
• 8.6 Novartis
  • 8.6.1 Marketed Dermatological Product Portfolio
  • 8.6.2 R&D Pipeline Analysis
  • 8.6.3 Strategic Analysis
• 8.7 Roche
  • 8.7.1 Marketed Dermatological Product Portfolio
  • 8.7.2 Strategic Analysis
• 8.8 Stiefel Laboratories
  • 8.8.1 Marketed Dermatological Product Portfolios
  • 8.8.2 R&D Pipeline Analysis
  • 8.8.3 Strategic Analysis
• 8.9 Bayer Schering Pharma
  • 8.9.1 Marketed Dermatological Product Portfolio
  • 8.9.2 R&D Pipeline Analysis
  • 8.9.3 Strategic Analysis
• 8.10 Schering-Plough
  • 8.10.1 Marketed Dermatological Product Portfolio
  • 8.10.2 R&D Pipeline Analysis
  • 8.10.3 Strategic Analysis
• 8.11 Sanofi-Aventis
  • 8.11.1 Marketed Dermatological Product Portfolio
  • 8.11.2 Strategies Analysis
• 8.12 Others
  • 8.12.1 Eisai
  • 8.12.2 Ipsen

Chapter 9 New Technology Developments and Strategic Analysis

• 9.1 New Technology Pipeline Developments
• 9.2 Macro-environmental Analysis
  • 9.2.1 Potential entrants
  • 9.2.2 Supplier Bargaining Power
  • 9.2.3 Consumer Bargaining Power
  • 9.2.4 Substitutes Threats
  • 9.2.5 Rivals Competitions
• 9.3 Strategic Analysis
  • 9.3.1 SWOT Analysis

Chapter 10 Conclusion

• 10.1 A Review for Current Dermatological Market
• 10.2 The Analysis for Future Dermatological Market
  • 10.2.1 Sales Performance
  • 10.2.2 Market Share
• 10.3 Strategy Analysis

List of Tables

• Table 1.1 The Sales Performance of Dermatological Markets ($M)
• Table 3.1 Acne Prevalence in the Major Seven Markets (' 000)
• Table 3.2 Marketd Topical Clindamycin Drugs in 2006
• Table 3.3 Marketed Topical Retinoid Agents in 2006
• Table 3.4 Marketed Oral Retinoid Agents in 2006
• Table 3.5 Marketed Estrogen Agents in 2006
• Table 3.6 Acne Market Performance (2003-2006)
• Table 3.7 Leading Anti-Acne Treatments in 2006
• Table 3.8 The Sales Performance of Leading Anti-Acne Treatments in ' 05/' 06
• Table 3.9 Leading Topical Anti-Acne Treatments in 2006
• Table 3.10 The Sales Performance of Leading Topical Anti-Acne Treatments in ' 05/' 06
• Table 3.11 Leading Oral Anti-Acne Treatments in 2006
• Table 3.12 The Sales Performance of Leading Anti-Acne Treatments in ' 05/' 06
• Table 3.13 Sales Forecasts of Topical Acne Treatments (' 07-' 22)
• Table 3.14 Sales Forecasts of Oral Acne Treatments (' 07-' 22)
• Table 3.15 Sales Forecasts(M) for Global Acne Market (' 07-' 22)
• Table 4.1 Psoriasis Prevalence in the Major Seven Markets (' 000)
• Table 4.2 Marketed Psoriasis Vitamin D3 Analogues in 2006
• Table 4.3 Global Anti-Psoriasis Market ($M)
• Table 4.4 Leading Psoriasis Treatments in 2006
• Table 4.5 The Sales Performance of Leading Psoriasis Treatments in 2006 ($M)
• Table 4.6 Sales Forecasts (M) of Psoriasis Treatments (2007-2022)
• Table 5.1 Bacteria Infection Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 5.2 Fungal Infection Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 5.3 Viral Infection Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 5.4 Sales Performance of Dermatological Infective Treatments ($M)
• Table 5.5 Leading Dermatological Anti-Infective Treatments in 2006
• Table 5.6 Sales Performance of Leading Anti-Infective Treatments ($M)
• Table 5.7 Sales Forecasts of Anti-Infective Treatments (2007-2022)
• Table 6.1 Atopic Dermatitis Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 6.2 Rosacea Prevalence in the Seven Major Markets in 2005 (' 000)
• Table 6.3 Sales Performance of Corticosteroids ($M) 2003 to 2006
• Table 6.4 Leading Corticosteroid Agents in 2006
• Table 6.5 The Sales Performance of Leading Corticosteroids ($M)
• Table 6.6 Sales Forecasts of Corticosteroids ($M) 2007-2022
• Table 6.7 Sales Performance of Other Dermatological Treatments ($M)
• Table 6.8 Leading Other Dermatological Products (2006)
• Table 6.9 Sales Performance of Leading Other Dermatological Products (2005/2006)
• Table 6.10 Sales Forecasts of Other Dermatological Treatments ($M)
• Table 7.1 Top Five Cosmetic Procedures in the US in 2006
• Table 7.2 Sales Performance of Leading Botulinum Toxin ($M)
• Table 7.3 Leading Botulinum Toxin in 2006
• Table 7.4 Sales Forecasts of Botulinum Toxin ($M) 2007-2022
• Table 8.1 Guidelines for Botox Outside of the US in 2006
• Table 8.2 GSK' s Main Dermatological Products (2006)
• Table 8.3 J&J' s Sales Performance of Marketed Products ($M)
• Table 8.4 J&J' s Leading Dermatological Products ($M)
• Table 8.5 J&J' s Dermatological Pipeline Development (2006
• Table 8.6 L' Oreal' s Marketed Dermatological Products ($M) in 2006
• Table 8.7 L' Oreal' s Leading Dermatological Products in 2006
• Table 8.8 Leo Pharma' s Market Dermatological Products ($M) in 2006
• Table 8.9 Leo Pharma' s Leading Dermatological Products ($M) in 2006
• Table 8.10 Leo Pharma' s Dermatological R&D in 2006
• Table 8.11 Novartis' Marketed Dermatological Products ($M) in 2006
• Table 8.12 Novartis' Leading Dermatological Products in 2006
• Table 8.13 Novartis' Dermatological Pipeline Developments in 2006
• Table 8.14 Roche' s Marketed Dermatological Products ($M)
• Table 8.15 Roche' s Leading Dermatological Products in 2006
• Table 8.16 Stiefel' s Marketed Dermatological Rpoducts ($M) in 2006
• Table 8.17 Stiefel' s Leading Dermatological Products in 2006
• Table 8.18 Stiefel' s Dermatological Pipeline Developments in 2006
• Table 8.19 Bayer' s Marketed Dermatological Products ($M) in 2006
• Table 8.20 Bayer' s Leading Dermatological Products in 2006
• Table 8.21 Schering-Plough' s Marketed Dermatological Treatments ($M)
• Table 8.22 Schering-Plough' s Leading Dermatological Products in 2006
• Table 8.23 Sanofi-Aventis' Marketed Dermatological Products ($M)
• Table 8.24 Sanofi-Aventis' Leading Dermatological Products in 2006
• Table 9.1 SWOT Analysis for Dermatological Market
• Table 10.1 Sales Performance of Dermatological Market ($M) 2003-2006
• Table 10.2 Sales Forecasts for Dermatological Markets ($M) 2007-2022
• Table 10.3 Market Share of Dermatological Treatments, 2006, 2012 and 2022

List of Figures

• Figure 1.1 Market Share of Dermatological Market in 2006
• Figure 1.2 Strategic Performance of Dermatological Treatments in 2006
• Figure 3.1 Market Share of Acne Treatments in 2006
• Figure 3.2 The Strategic Performance of Topical Anti-Acne Treatments in 2006
• Figure 3.3 Strategic Performance of Oral Anti-Acne Treatments in 2006
• Figure 3.4 Sales Forecasts (M) of Global Acne Market (2007-2022)
• Figure 4.1 The Factors Influencing Psoriasis Treatments
• Figure 4.2 Strategic Performance of Leading Psoriasis Treatments in 2006
• Figure 4.3 Sales Performance of Psorasis Treatments ($M)
• Figure 5.1 Sales Performance of Dermatological Anti-Infective Market ($M)
• Figure 5.2 Strategic Performance of Anti-Infective Market (2006)
• Figure 5.3 Strategic Performance of Laeding Anti-Infective Treatments in 2006
• Figure 6.1 Sales Performance of Corticosteroids ($M) 2003-2006
• Figure 6.2 Strategic Performance of Corticosteroids in 2006
• Figure 6.3 Market Share of Leading Corticosterods (2006)
• Figure 6.4 Market Share of Other Dermatological Products (2006)
• Figure 6.5 Strategic Performance of Other Dermatological Products (2006)
• Figure 6.6 Strategic Performance of Leading Other Dermatological Products (2006)
• Figure 7.1 Expenditure of Cosmetic Surgical Procedure in the US (2006)
• Figure 7.2 Expenditure of Cosmetic Non-Surgical Procedure in US (2006)
• Figure 7.3 Sales Forecasts of Botulinum Toxin ($M) 2007-2022
• Figure 8.1 Sales Share of Botox in Different Usage (06)
• Figure 8.2 Sales of Botox in Major Countries (2004-2006)
• Figure 8.3 USage of Zovirax (2006)
• Figure 8.4 Leading Products in J&J (' 06)
• Figure 8.5 L' Oreal' s Leading Products in 2006
• Figure 8.6 Leo Pharma' s Leading Products in 2006
• Figure 8.7 Novartis' Leading Dermatological Products in 2006
• Figure 8.8 Novartis' Leading Dermatological Products ($M) 2003-2006
• Figure 8.9 Roche' s Leading Dermatological Products (2006)
• Figure 8.10 Stiefel' s Leading Dermatological Products in 2006
• Figure 8.11 Bayer' s Leading Dermatological Products in 2006
• Figure 8.12 Schering-Plough' s Leading Products in 2006
• Figure 8.13 Sanofi-Aventis' Leading Dermatological Products in 2006
• Figure 9.1 The Factors Impacts Pipeline Developments
• Figure 9.2 Porter-Five-Forces Analysis for Dermatological Market
• Figure 10.1 Market Share of Dermatological Products in 2006
• Figure 10.2 Strategic Performance of Dermatological Treatments in 2006

Organisations mentioned in the report

• Agis Industries
• Alcon
• Allergan
• Altana
• American Society for Aesthetic Plastic Surgery
• Astellas
• Barr
• Bayer
• Bioglan
• BMS
• ColBar LifeScience Ltd
• Connetics/Stiefel
• Cougar Biotechnology
• DreamPharma Corporation
• Eisei Co
• Eli Lilly
• Esteve
• Eurofarma
• Expanscience
• FDA
• Fumedica
• Galderma
• Gedeon Richter
• Genentech
• GenPharm
• Graceway Pharma
• Gruenenthal
• GSK
• Idexx
• IMS
• Inamed
• Ipsen
• Johnson&Johnson
• LEO Pharma
• Loreal
• Medicis
• Merck &Co.
• Merz
• Minnesota 3M
• Mylan
• Nestle
• Novartis
• Nycomed Pharma
• Ortho
• Penederm
• Perrigo
• Pfizer
• Pieer Fabre
• Q-Med
• Ranbaxy
• Ratiopharm
• Roche
• Sanofi-Aventis
• Schering-Plough
• Shionogi
• Stiefel Labs
• Taro
• Valeant
• Warner Chilcott